Lobe Sciences Ltd.

Lobe Sciences Ltd.

Lobe Sciences Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it intends to raise up to Cdn$2,000,000 (the "Offering") through a non-brokered private placement of up to 20,000,000 units (the "Units") at a price of Cdn$0.10 per Unit... Read More...

Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors

Appointment of Jonathan Gilbert as Executive Chairman allows Lobe to capitalize on his significant capital markets experienceVancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that the appointment of Mr. Jonathan Gilbert as E... Read More...

Lobe Sciences Commences Engineering of Nasal Mist Device

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has engaged VisionWorks Engineering of San Diego, CA to commence engineering work to complete and test a proof of concept prototype of its nasal mist device.This is a ... Read More...

Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.

Signed LOI for CAD$23 million sale to Ionic provides shareholder valueVancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has received and signed a non-binding letter of intent dated November 30, 2020 with IONIC Brands ... Read More...

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine ("NAC") for the treatment of mild traumatic brain injury/concussion ("mTBI") with post-trauma... Read More...